Network meta‐analyses of randomized controlled trials (RCTs) have shown that newer therapies targeting interleukin (IL)‐23 p19 and IL‐17 are more efficacious than the older biologics such as tumour necrosis factor (TNF)‐α inhibitors and ustekinumab, an IL‐12/23 inhibitor, for the treatment of psoriasis.1 The gene discussed is IL17A; the disease is psoriasis.